Steroid inhibitor
The clinical development of a 5α-reductase inhibitor, finasteride

https://doi.org/10.1016/0960-0760(90)90487-6Get rights and content

Abstract

Finasteride, a 4-aza steroid compound, is an orally active inhibitor of the 5α-reductase enzyme. 5α-Reductase is necessary for the metabolism of testosterone (T) to dihydrotestosterone (DHT) and is found in high levels only in certain tissues such as the prostate. Finasteride has been shown to markedly suppress serum DHT levels in man without lowering testosterone levels. In patients with benign prostate hyperplasia (BPH), finasteride was found to decrease prostate volume by a mean of 28% over a period of 6 months, without causing clinically significant adverse effects. DHT appears to be the primary androgen for prostatic growth. Selective inhibition of 5α-reductase by finasteride may provide a novel approach to BPH therapy by reducing prostate size without affecting T-dependent processes such as fertility, muscle strength, and libido. The clinical development of finasteride for the treatment of benign prostate hyperplasia is reviewed.

References (12)

  • J.R. Carlin et al.

    High-performance liquid chromatographic determination of N-(2-methyl-2-propyl 3-oxo-4 aza-5α-androst-1-ene-17b-carboxamide. A 4-Aza steroid in human plasma from a phase I study

    J. Chromat.

    (1988)
  • N.P. Roos et al.

    Mortality and reoperation after open and transurethral resection of the prostate of benign prostatic hyperplasia

    New Engl. J. Med.

    (1989)
  • G.H. Rasmusson

    Biochemistry and pharmacology of 5α-reductase Inhibitors

  • P.C. Walsh et al.

    Familial incomplete male pseudohermaphroditism type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias

    New Engl. J. Med.

    (1974)
  • J. Imperato-McGinley et al.

    Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism

    Science

    (1974)
  • R.S. Rittmaster et al.

    Effect of MK-906, a specific 5α-reductase inhibitor on serum androgens and androgen conjugates in normal men

    J. Androl.

    (1989)
There are more references available in the full text version of this article.

Cited by (217)

  • Anti-androgenic therapy with finasteride improves cardiac function, attenuates remodeling and reverts pathologic gene-expression after myocardial infarction in mice

    2018, Journal of Molecular and Cellular Cardiology
    Citation Excerpt :

    In this regard, we have recently demonstrated that the anti-androgenic medication finasteride, which is currently widely used in patients to counteract benign prostate hyperplasia, reduces cardiac hypertrophy and cardiac dysfunction in mice during experimental pressure overload by transverse aortic constriction (TAC) [15]. Finasteride acts by inhibiting the isoforms two and three of the 5-alpha reductase (Srd5a2, Srd5a3) that catalyze the generation of the highly active metabolite dihydrotestosterone (DHT) from testosterone, and that become induced in pressure overload hypertrophy in mice and in the myocardium of patients with heart failure [15] [16,17]. DHT is known to induce hypertrophy and we had observed increased DHT levels in hypertrophied mouse and human hearts [15,18].

  • 5-Alpha-Reductase Inhibitors and Combination Therapy

    2016, Urologic Clinics of North America
    Citation Excerpt :

    According to current guidelines, both 5ARIs can be used in the treatment of BPH with lower urinary tract symptoms (LUTS), either alone or in combination with other drugs targeting BPH/LUTS.8,9 After several animal experiments, MK-906 (which later became FIN) was successfully tested for safety, tolerability, and biochemical activity in 350 volunteers.10 In healthy men, MK-906 reduced serum DHT levels by −62% to −82% without affecting serum testosterone levels.11,12

  • Evaluation of the 5α-reductase inhibitor finasteride on reproduction and gonadal development in medaka, Oryzias latipes

    2015, General and Comparative Endocrinology
    Citation Excerpt :

    If 5αR has a role in fish steroid biosynthesis and a function in fish androgen signaling, via DHT, then exposure to a 5αR inhibitor should induce anti-androgenic responses like those observed in higher vertebrates. Finasteride (FIN) is a type-2 5αR inhibitor and is a pharmaceutical used in the treatment of a number of human diseases including prostate cancer, benign prostate hyperplasia and male pattern baldness (Stoner, 1990). Type-2 5αR is primarily expressed in genital tissues (Azzouni et al., 2012).

  • Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain

    2014, Progress in Neurobiology
    Citation Excerpt :

    Furthermore, corrective AP treatment repaired VINC or OXAL-induced nerve tissue damages by restoring normal density of intraepidermal nerve fibers in hind paw intraplantar skins and control expression level of neurofilament 200 kDa in VINC- or OXAL-treated rat dorsal root ganglia and sciatic nerves (Meyer et al., 2010, 2011). It is also important to discuss our results showing that the inhibition of progesterone conversion into 5α-reduced metabolites (dihydroprogesterone and AP) by finasteride (Finn et al., 2006; Stoner, 1990) completely blocked antinociceptive, analgesic and neuroprotective effects exerted by progesterone against VINC-induced painful neuropathy. In fact, in the absence of finasteride, progesterone may be converted to the potent progesterone nuclear receptor agonist dihydroprogesterone (Brann et al., 1990) and to the neuroprotector AP (Melcangi et al., 2008), allowing therefore a strong stimulation or optimal activities of biochemical and neuroanatomical/neurochemical components in peripheral nerves such as CNPase, axonal constitutive proteins/transporters and intraepidermal nerve fibers (IENF).

View all citing articles on Scopus
View full text